Researchers from Charité – Universitäts medizin Berlin have found that statins, commonly prescribed to lower cholesterol, do not provide additional antidepressive benefits for patients with depression and obesity. The study, published in JAMA Psychiatry, involved 161 participants and confirmed that traditional antidepressants remain the most effective treatment for depression.
The study aimed to investigate whether statins, which have anti-inflammatory properties, could also alleviate depression in obese patients, a group at higher risk for both conditions. Participants were divided into two groups: one received a standard antidepressant plus simvastatin (a statin), while the other received the antidepressant plus a placebo. Over 12 weeks, both groups showed similar improvements in depression symptoms, with no significant difference between them.
Blood tests confirmed that statins effectively reduced cholesterol and inflammatory markers like CRP, but these changes did not translate into enhanced antidepressive effects. “Administering statins improved lipid levels and reduced inflammation, but it did not amplify the antidepressant response,” explained Dr. Woo Ri Chae, a co-lead author of the study.
Prof. Christian Otte, the study’s leader, emphasized: “Statins should be prescribed to lower cardiovascular risk, not to treat depression. Traditional antidepressants remain the gold standard.”
The findings reinforce current medical guidelines, recommending statins solely for cholesterol management. The research team plans further analysis of blood samples to explore cellular-level correlations and continues to investigate improved treatments for depression in patients with comorbid conditions.
Add comment